WuXi Biologics (Cayman) Balance Sheet Health
Financial Health criteria checks 5/6
WuXi Biologics (Cayman) has a total shareholder equity of CN¥44.6B and total debt of CN¥2.2B, which brings its debt-to-equity ratio to 4.8%. Its total assets and total liabilities are CN¥56.1B and CN¥11.5B respectively. WuXi Biologics (Cayman)'s EBIT is CN¥3.5B making its interest coverage ratio -18.3. It has cash and short-term investments of CN¥9.5B.
Key information
4.8%
Debt to equity ratio
CN¥2.16b
Debt
| Interest coverage ratio | -18.3x |
| Cash | CN¥9.53b |
| Equity | CN¥44.64b |
| Total liabilities | CN¥11.46b |
| Total assets | CN¥56.11b |
Recent financial health updates
Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly
Apr 15
Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
Sep 08Recent updates
Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why
Jun 12Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%
Jun 11Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding
Jun 11Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly
Apr 15Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge
Mar 04Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade
Dec 08Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Nov 10What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
Sep 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate
Aug 10Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?
Jun 19Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
May 12Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?
Mar 13Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?
Feb 13An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued
Jan 30Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching
Nov 20With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case
Nov 08Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?
Oct 27WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
Sep 08Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?
Aug 15We Ran A Stock Scan For Earnings Growth And WuXi Biologics (Cayman) (HKG:2269) Passed With Ease
Aug 02Estimating The Intrinsic Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Jun 29What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
May 16Financial Position Analysis
Short Term Liabilities: 2269's short term assets (CN¥19.8B) exceed its short term liabilities (CN¥6.8B).
Long Term Liabilities: 2269's short term assets (CN¥19.8B) exceed its long term liabilities (CN¥4.7B).
Debt to Equity History and Analysis
Debt Level: 2269 has more cash than its total debt.
Reducing Debt: 2269's debt to equity ratio has increased from 0% to 4.8% over the past 5 years.
Debt Coverage: 2269's debt is well covered by operating cash flow (216.4%).
Interest Coverage: 2269 earns more interest than it pays, so coverage of interest payments is not a concern.